A phase II/III, multicenter, open-label, multicohort, two-part study evaluating Pharmacokinetics (PK), safety, and efficacy of cobicistat-boosted Atazanavir (ATV/co) or cobicistat-boosted Darunavir (DRV/co), administered with Background Regimen (BR) in HIV-1 infected, treatment-experienced, virologically suppressed pediatric subjects

Project no.: HIV-NAT 208/GS-US-216-0128 (NCT02016924)

This study will evaluate the steady-state pharmacokinetics (PK) and confirm the dose of cobicistat-boosted atazanavir (ATV/co) or cobicistat-boosted darunavir (DRV/co) in HIV-1 infected antiretroviral treatment-experienced pediatric participants between the ages of 3 months to < 18 years of age.

It will also evaluate the safety, tolerability, and efficacy of ATV/co or DRV/co each co-administered with a background regimen (BR) through 48 weeks and during long-term treatment (total of 5 years).